Infantile Spinal Muscular Atrophy Clinical Trials
2 recruiting trials for Infantile Spinal Muscular Atrophy. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Infantile Spinal Muscular Atrophy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Centre Hospitalier Universitaire de Saint Etienne (1), Assistance Publique - Hôpitaux de Paris (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Thumb test (other, 1 trial), followed by Grip test, Quadriceps Intermittent Fatigue test (QIF test)).
Track Infantile Spinal Muscular Atrophy trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by the degeneration of motor neurons in the anterior horn of the spinal cord, due to the...
Test of Aquatic Mobility of SMA Infants
Spinal muscular atrophy (SMA) is a genetic neurodegenerative disease impacting spinal cord motor neurons, leading to motor and respiratory issues and, ultimately, death. With...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Infantile Spinal Muscular Atrophy, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Infantile Spinal Muscular Atrophy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Infantile Spinal Muscular Atrophy, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.